Wechat

Website

Chinese Journal of Oncology Prevention and Treatment

• Article • Previous Articles     Next Articles

Analysis on prognosis and response to chemotherapy of triplenegative breast cancer

CAO Yi-lin,XU Li-rong,QU Yuan-jiao,et al.   

  1. (Department of Medical Oncology,The Second Hospital of GuangXi Zhuang automomous Region,Guilin 541002,China
  • Received:2009-03-25 Revised:2009-03-25 Online:2009-03-25 Published:2009-03-25

Abstract: Objective To evaluate the response to chemotherapy and the prognosis of triple-negative breast cancer(TNBC)by comparing to the non-TNBC.Methods 147 advanced breast carcinoma patients were defined negative expresions of estrogenr eceptor(ER),progesterone receptor(PR) and human epidermal growth factor rector 2(Her-2 ) by immunohistochemistry. Paclitaxel or Docetaxel was administered intravenously at a dose of 135mg/m~2(or 75 mg/m~2)on d1,Cisplatin 30mg/m~2 from d1 to d3.A treatment cycle was 21 days.After 2 cycles,the pathologic parameters,the treatment efficacy and the prognosis were compared between the patients of TNBC and non-TNBC.Results 20 of 147 patients(13.6%) were TNBC.Patients of TNBC had higher overall response rate compared with non-TNBC(P = 0.048 ).The median progression free survial time in the patients of TNBC and non-TNBC were 5.5 months and 6.5 months respectively.There were significant difference between the two groups at primary tumor size(P =0.042).Conclusion Paclitaxel or Docetaxel combined with Cisplatin chemotherapy regimen was sensitive in TNBC,but the median progression free survial time was worse in this group.

Key words: Breast neoplasma, ER, PR, Her-2, Chemotherapy